Clinical trial Recruiting at 3 sites Phase 2 Interventional Ages 18 and up

Using intravenous iron to treat anemia after heart surgery

Official title: Post-operative Intravenous Iron to Treat Iron-deficiency Anemia in Patients Undergoing Cardiac Surgery: A Pilot, Multi-centre, Placebo-controlled Randomized Trial.

Run by University Health Network, Toronto · NCT06287619 · Data updated 2026-11-12

This study is testing if giving intravenous iron to patients with anemia after heart surgery can help them stay out of the hospital and feel better.

More Cardiac Surgery trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment60 (estimated)
SponsorUniversity Health Network, Toronto
Academic / other
Locations3 sites (Kingston, Ontario and 2 other locations)
StatusRecruiting
StartedApril 3, 2025
Main results expectedDecember 2026
Study endsJune 2027
Registry record updatedFebruary 10, 2026
Trial IDNCT06287619 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults over 18 years old with preoperative iron-deficiency anemia scheduled for non-emergency cardiac surgery involving cardiopulmonary bypass.

Probably not a fit

Patients with contraindications to intravenous iron or those undergoing specialized cardiac procedures may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, randomized, controlled pilot trial aims to evaluate the feasibility of a larger study investigating the effects of intravenous iron therapy on patients with chronic iron-deficiency anemia undergoing cardiac surgery. Participants will receive either the iron treatment or a placebo shortly after surgery, with a follow-up dose at 42 days if necessary. The primary outcome measure will be the number of days alive and out of the hospital within 90 days post-surgery. The trial is being conducted at three cardiac surgery centers in Canada.

Why it matters

Potential benefit: If successful, this approach could significantly improve recovery outcomes for patients with anemia undergoing cardiac surgery.

How similar studies have gone: Previous studies have shown promising results with intravenous iron therapy in similar patient populations, suggesting potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Patients who are undergoing any non-emergency open cardiac surgery and who meet all following criteria:

1. Age greater than 18 years old
2. Preoperative iron-deficiency with or without anemia (defined as Hb \<130 g/L) with any one of:

   1. ferritin ≤100 μg/l; or
   2. ferritin ≤ 300 μg/L and transferrin saturation ≤ 20%; or
   3. reticulocyte Hb content \< 29 pg, where available

Exclusion Criteria:

Patients who meet any of the following criteria are not eligible for the study:

1. specialized procedures (e.g., ventricular assist device insertion, thoracoabdominal aneurysm, complex adult congenital surgery and heart transplant)
2. established contraindications to IV iron:

   1. hypersensitivity to the iron product
   2. history of \>2 food and/or drug allergic reactions (excluding drug intolerance)
   3. non-iron deficiency anemias such as myelodysplastic syndrome
   4. history of iron overload or disturbances in use of iron such as hemochromatosis or hemosiderosis
   5. decompensated liver cirrhosis (MELD ≥ 19) or active hepatitis
   6. active infection
3. preoperative unstable hemodynamics defined as the requirement for vasopressors or inotropes, or active bleeding (as noted in the clinical record and/or defined as a requirement for red blood cell transfusion for ongoing clinical bleeding)
4. refusal of blood products for religious or other reasons
5. known pregnancy
6. already enrolled in this trial
7. enrolment in another interventional trial which may impact anemia or transfusion management (for example, a trial of hemostatic therapies, such as tranexamic acid)
8. receipt of intravenous iron at any point in the 6 weeks prior to randomization

Where it's running

  • Kingston Health Sciences Centre
    Kingston, Ontario, Canada
    Recruiting
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario, Canada
    Recruiting
  • Toronto General Hospital - University Health Network
    Toronto, Ontario, Canada
    Recruiting

Study contacts

  • Principal investigator: Justyna Bartoszko, MD — University Health Network, Toronto
  • Study coordinator: Keyvan Karkouti, MD
  • Email: Keyvan.Karkouti@uhn.ca
  • Phone: 416-340-4800

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.